Levodopa-induced hyperhomocysteinaemia in Parkinson's disease

Acta Neurologica Scandinavica

Volumn 108, Issue 1, 2003, Pages 66-67

  Yasui, K ^a   Nakaso, K ^a   Kowa, H ^a   Takeshima, T ^a   Nakashima, K ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; CLINICAL ARTICLE; DEGENERATIVE DISEASE; DRUG INDUCED DISEASE; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; LETTER; PARKINSON DISEASE; VITAMIN SUPPLEMENTATION;

ANTIPARKINSON AGENTS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; PARKINSON DISEASE;

EID: 0038385259     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00135.x     Document Type: Letter

References (6)

1. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-40.
2. Kuhn W, Roebroek R, Blom H et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-7.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
4. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13.
5. Nakaso K, Yasui K, Kowa H et al . Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with levodopa, homocysteine, and MTHFR genotype. J Neurol Sci 2003;207:19-23.
6. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57:1422-7.